



# Meccanismi fisiopatologici dell'hypotensive susceptibility dell'anziano

Martina Rafanelli, MD, PhD

Syncope Unit , SOD di Geriatria e UTIG, Università degli Studi di Firenze, Azienda Ospedaliero-Universitaria Careggi, Firenze





Twenty-eight years of research permit reinterpretation of tilt-testing: hypotensive susceptibility rather than diagnosis


Richard Sutton<sup>1\*</sup> and Michele Brignole<sup>2</sup>

### Suscettibilità ipotensiva

Tendenza alla vasodepressione che può favorire la tpdc, indipendentemente dal meccanismo eziologico dominante la sincope.

### Benefit of Pacemaker Therapy in Patients With Presumed Neurally Mediated Syncope and Documented Asystole Is Greater When Tilt Test Is Negative

An Analysis From the Third International Study on Syncope of Uncertain Etiology (ISSUE-3)



### Benefit of Pacemaker Therapy in Patients With Presumed Neurally Mediated Syncope and Documented Asystole Is Greater When Tilt Test Is Negative

An Analysis From the Third International Study on Syncope of Uncertain Etiology (ISSUE-3)

the benefit of pacemaker therapy in patients with presumed NMS and documented asystole was not substantial in those with a positive TT

...we speculate that pacing failure was because of hypotensive syncope...


hypotension plays a major role in all forms of TT-induced NMS and precedes/triggers bradycardia and syncope in the vast majority of patients even in those with cardioinhibitory syncope

Ashish Chaddha<sup>1</sup> · Martina Rafanelli<sup>2</sup> · Michele Brignole<sup>3</sup> · Richard Sutton<sup>4</sup> · Kevin E. Wenzke<sup>1</sup> · Stephen L. Wasmund<sup>1</sup> · Richard L. Page<sup>1</sup> · Mohamed H. Hamdan<sup>1</sup>

	All VVS $(n = 366)$	Tilt positive $(n = 275)$	Tilt negative $(n = 91)$	(+) vs (-) p value
Mean age (year)	$48 \pm 20$	$50 \pm 21$	42 ± 18	0.002
Gender (M/F)	127/239	93/182	34/57	0.63
Mean EF (%)	$64 \pm 4$	$64 \pm 5$	$65 \pm 5$	0.14
Diabetes: n (%)	21 (6)	14 (5)	7 (8)	0.51
Hypertension: n (%)	86 (23)	72 (26)	14 (15)	0.05
Prodromes present: $n$ (%)	239 (65)	173 (63)	66 (73)	0.12
Multiple events: $n$ (%)	114 (31)	90 (33)	24 (26)	0.32
Autonomic symptoms: n (%)	214 (58)	120 (44)	32 (35)	0.19
Medications				
Beta-blockers: n (%)	79 (22)	56 (20)	23 (25)	0.40
$Ca^{2+}$ channel blockers: $n$ (%)	8 (2)	4 (1)	4 (4)	0.21
Mean BRG (ms/mmHg)	$12.5 \pm 6.3$	$12.5 \pm 6.3$	$12.4 \pm 6.3$	0.72

EF ejection fraction; BRG baroreflex gain


Ashish Chaddha<sup>1</sup> · Martina Rafanelli<sup>2</sup> · Michele Brignole<sup>3</sup> · Richard Sutton<sup>4</sup> · Kevin E. Wenzke<sup>1</sup> · Stephen L. Wasmund<sup>1</sup> · Richard L. Page<sup>1</sup> · Mohamed H. Hamdan<sup>1</sup>



Mean BRG decreased with increasing age.


This relationship was seen in all patients, in tilt-positive and tilt-negative patients

Ashish Chaddha<sup>1</sup> · Martina Rafanelli<sup>2</sup> · Michele Brignole<sup>3</sup> · Richard Sutton<sup>4</sup> · Kevin E. Wenzke<sup>1</sup> · Stephen L. Wasmund<sup>1</sup> · Richard L. Page<sup>1</sup> · Mohamed H. Hamdan<sup>1</sup>



Concomitant with the decrease in BRG, the prevalence of a vasodepressor response increased in older subjects.

Ashish Chaddha<sup>1</sup> · Martina Rafanelli<sup>2</sup> · Michele Brignole<sup>3</sup> · Richard Sutton<sup>4</sup> · Kevin E. Wenzke<sup>1</sup> · Stephen L. Wasmund<sup>1</sup> · Richard L. Page<sup>1</sup> · Mohamed H. Hamdan<sup>1</sup>



The HR was significantly by the HR was significantly by the Horizon With the tilt-negative VVS patients et all preasured time points.

Ashish Chaddha<sup>1</sup> · Martina Rafanelli<sup>2</sup> · Michele Brignole<sup>3</sup> · Richard Sutton<sup>4</sup> · Kevin E. Wenzke<sup>1</sup> · Stephen L. Wasmund<sup>1</sup> · Richard L. Page<sup>1</sup> · Mohamed H. Hamdan<sup>1</sup>

Indeed, the presence of a blunted HR response in subjects with positive TTT supports the hypothesis that tilt-induced hypotension is primarily due to a drop in cardiac output with the HR playing a role. It is important to note that a


Ashish Chaddha<sup>1</sup> · Martina Rafanelli<sup>2</sup> · Michele Brignole<sup>3</sup> · Richard Sutton<sup>4</sup> · Kevin E. Wenzke<sup>1</sup> · Stephen L. Wasmund<sup>1</sup> · Richard L. Page<sup>1</sup> · Mohamed H. Hamdan<sup>1</sup>

There are possible explanations for the blunted HR response:


greater HR variability during TTT in patients with tiltpositive VVS when compared to patients with tiltnegative VVS;


Age-related sinus node dysfunction


Noninvasive beat-to-beat finger arterial pressure monitoring during orthostasis: a comprehensive review of normal and abnormal responses at different ages




the initial biphasic HR response on active standing decreases with age; the primary peak at 3 s is no longer present in old age








**Diagnostic criteria:** Abnormal BP fall is defined as a progressive and sustained fall in systolic BP from baseline value  $\geq 20$  mmHg or diastolic BP  $\geq 10$  mmHg, or a decrease in systolic BP to < 90 mmHg.



A delayed BP recovery is the inability of systolic BP to recover to >20 mmHg below baseline value at 30 s of standing

### Age-Related Normative Changes in Phasic Orthostatic Blood Pressure in a Large Population Study

Findings From The Irish Longitudinal Study on Ageing (TILDA)



The active stand response in a selected TILDA (The Irish Longitudinal Study on Ageing) participant. Beat-to-beat systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) waveforms are shown.

### Age-Related Normative Changes in Phasic Orthostatic Blood Pressure in a Large Population Study

Findings From The Irish Longitudinal Study on Ageing (TILDA)

Table 3. Prevalence of IOH, Impaired Blood Pressure Stabilization, and OH Stratified by Age, Sex, and Time Since Stand (n=4475)

	ЮН	OH Nadir	OH(10)	OH(20)	OH(30)	OH(40)
Men	35.6 (33.3–38.0)	96.7 (95.8–97.5)	85.1 (83.3–86.8)	28.1 (25.7–30.6)	16.4 (14.4–18.3)	14.3 (12.4–16.1)
Women	30.4 (28.0–32.8)	96.1 (95.1–97.1)	81.1 79.0–83.3)	35.9 (33.3–38.4)	21.2 (18.9–23.5)	16.9 (14.7–19.2)
Age, y						
50–59	35.0 (32.8–37.2)	96.7 (95.9–97.5)	82.6 (80.8–84.4)	21.2 (19.1–23.3)	11.3 (9.8–12.9)	9.1 (7.7–10.5)
60–69	31.1 (28.6–33.6)	96.2 (95.1–97.2)	83.5 (81.4–85.5)	33.2 (30.6–35.8)	17.9 (15.9–20.0)	14.3 (12.4–16.3)
70–79	32.4 (27.7–37.1)	95.6 (93.5–97.8)	83.0 (78.8–87.2)	48.0 (42.9–53.1)	31.0 (26.2–35.8)	25.7 (21.1–30.4)
≥80	29.8 (19.6–40.1)	98.1 (95.7–100.4)	84.7 (75.8–93.6)	57.9 (46.7–69.1)	43.1 (32.0–54.1)	41.2 (30.0–52.4)

In the full TILDA cohort, there was a marked age gradient in the proportion with BP that failed to stabilize within 40 s of standing, from 9.1% of the 50- to 59-year-old subjects to 41.2% of those ≥80 years

Association between orthostatic hypotension and cardiovascular risk, cerebrovascular risk, cognitive decline and falls as well as overall mortality: a systematic review and meta-analysis


Anna Angelousi<sup>a</sup>, Nicolas Girerd<sup>b</sup>, Athanase Benetos<sup>c</sup>, Luc Frimat<sup>d</sup>, Sylvie Gautier<sup>c</sup>, Georges Weryha<sup>a</sup>, and Jean-Marc Boivin<sup>b</sup>

The main finding of our study is that, in the meta-regression of the available evidence, orthostatic hypotension is associated with an increase in ACM greater than 30%.

orthostatic hypotension is strongly and independently associated with an increased risk of cardiovascular and ischemic cardiac events.

## Impaired Orthostatic Blood Pressure Recovery Is Associated with Unexplained and Injurious Falls

	IRR/RR (95% CI)	Р
<b>All-Cause Falls</b>		
ЮН	1.10 (0.93-1.31)	0.250
OH(40)	1.23 (0.98-1.55)	0.074
ОН	1.40 (1.01-1.96)	0.044*
<b>Unexplained Falls</b>		
ЮН	0.92 (0.65-1.32)	0.657
OH(40)	1.52 (1.03-2.26)	0.039*
ОН	1.81 (1.06-3.09)	0.029*
Injurious Falls		
ЮН	0.94 (0.75-1.18)	0.582
OH(40)	1.29 (0.98-1.7)	0.068
ОН	1.58 (1.12-2.24)	0.010 <sup>†</sup>
Syncope		
IOH	0.75 (0.53-1.06)	0.101
OH(40)	0.94 (0.63-1.41)	0.774
ОН	1.20 (0.70-2.06)	0.505



Failure of systolic BP to stabilize by 40 s was significantly associated with increased relative risk of unexplained falls 2 years later with trends towards an increased relative risk of all-cause and injurious falls

## Low blood pressure levels for fall injuries in older adults: the Health, Aging and Body Composition Study

 $(N = 1819; age 76.6 \pm 2.9 years)$ 


	Total sample $N = 1819$	With fall injury $N = 570$	Without fall injury
			N = 1249
Systolic blood pressure (SBP), mmHg	134.7 ± 19.7	$135.1 \pm 20.6$	134.5 ± 19.2
SBP $\leq 120 \text{ mmHg}, n (\%)^{\text{a}}$	457 (25.1)	140 (24.6)	317 (25.4)
SBP $\leq 130 \text{ mmHg}, n (\%)^{\text{a}}$	849 (46.7)	261 (45.8)	588 (47.1)
SBP $\leq 140 \text{ mmHg}, n (\%)^{\text{a}}$	1221 (67.1)	376 (66.0)	845 (67.7)
SBP > 150 mmHg, $n$ (%)	314 (17.3)	102 (17.9)	212 (17.0)
Diastolic blood pressure (DBP), mmHg	$71.4 \pm 10.9$	$70.5 \pm 11.2^{b}$	$71.8 \pm 10.7$
$DBP \le 60 \text{ mmHg}, n (\%)^{a}$	329 (18.1)	125 (21.9) <sup>c</sup>	204 (16.3)
$DBP \le 70 \text{ mmHg}, n (\%)^{a}$	957 (52.6)	325 (57.0) <sup>b</sup>	632 (50.6)
$DBP \le 80 \text{ mmHg}, n (\%)^{a}$	1522 (83.7)	479 (84.0)	1043 (83.5)
DBP > 90  mmHg, n (%)	60 (3.3)	18 (3.2)	42 (3.4)

<sup>&</sup>lt;sup>a</sup>Blood pressure levels are not mutually exclusive

 $P < {}^{b}0.01, P < {}^{c}0.001$  (with vs. without fall injury)

## Low blood pressure levels for fall injuries in older adults: the Health, Aging and Body Composition Study

 $(N = 1819; age 76.6 \pm 2.9 years)$ 



DBP subgroups with ≤ 70 mmHg had the highest proportion of incident fall injury:

38% of participants with DBP ≤ 60 mmHg and 32% of those with 60 < DBP ≤ 70 mmHg






# Meccanismi fisiopatologici dell'hypotensive susceptibility dell'anziano

**Quale intervento?** 





## interactions between cardiovascular control and



Blaber A et al. Resp Physiol Neurobio 2009

# Orthostatic Intolerance in Older Persons: Etiology and Countermeasures



### Intolleranza Ortostatica...che fare?

intolerance. It is important, for example, when intervening in the process in which bedrest confinement leads to orthostatic intolerance and falls, that a holistic multifactorial approach which takes into account key factors such as nutrition, (de)conditioning, muscle loss, cardiovascular and vestibular effects, is followed.



### 2018 ESC Guidelines for the diagnosis and management of syncope

**ESC GUIDELINES** 

The Task Force for the diagnosis and management of syncope of the European Society of Cardiology (ESC)

#### Syncope due to OH

Note that hypotension may be exacerbated by venous pooling during exercise (exercise-induced), after meals (postprandial hypotension), and after prolonged bed rest

(deconditioning).

Drug-induced OH (most common cause of OH):

- e.g. vasodilators, diuretics, phenothiazine, antidepressants

Volume depletion:

- haemorrhage, diarrhoea, vomiting, etc.

Primary autonomic failure (neurogenic OH):

- pure autonomic failure, multiple system atrophy, Parkinson's disease, dementia with Lewy bodies

Secondary autonomic failure (neurogenic OH):

- diabetes, amyloidosis, spinal cord injuries, auto-immune autonomic neuropathy, paraneoplastic autonomic neuropathy, kidney failure

Compromissione Irreversibile del SNA

10 Neurogena



## 2018 ESC Guidelines for the diagnosis and management of syncope

**ESC GUIDELINES** 

The Task Force for the diagnosis and management of syncope of the European Society of Cardiology (ESC)

#### Syncope due to OH

Note that hypotension may be exacerbated by venous pooling during exercise (exercise-induced), after meals (postprandial hypotension), and after prolonged bed rest

(deconditioning).

Drug-induced OH (most common cause of OH):

- e.g. vasodilators, diuretics, phenothiazine, antidepressants

Volume depletion:

- haemorrhage, diarrhoea, vomiting, etc.

#### Compromissione Reversibile del SNA

Primary autonomic failure (neurogenic OH):

- pure autonomic failure, multiple system atrophy, Parkinson's disease, dementia with Lewy bodies


Secondary autonomic failure (neurogenic OH):

- diabetes, amyloidosis, spinal cord injuries, auto-immune autonomic neuropathy, paraneoplastic autonomic neuropathy, kidney failure



### 2018 ESC Guidelines for the diagnosis and management of syncope

The Task Force for the diagnosis and management of syncope of the European Society of Cardiology (ESC)




In assenza di ipertensione, I pz. devono essere istruiti ad assumere 2-3 lt di acqua/die e 10 g di NaCl.


Nell'ipotensione postprandiale, ingestione rapida di boli di acqua 500 cc.



#### Trattamento: sincope riflessa



There is moderate evidence that discontinuation/reduction of hypotensive therapy targeting a systolic BP of 140 mmHg should be effective in reducing syncopal recurrences in patients with hypotensive susceptibility. Further research is likely to



# The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension

Class of medications	Common examples		
Dopaminergic agents	Levodopa, dopamine agonists		
Antidepressants (particularly tricyclic agents) <sup>a</sup>	Amitriptyline, nortriptyline, imipramine, desipramine		
Anticholinergics	Atropine, glycopyrrolate, hyoscyamine		
Anti-hypertensive agents			
Preload reducers			
Diuretics <sup>a</sup>	Furosemide, torsemide, acetazolamide, hydrochlorothiazide, spironolactone		
Nitrates <sup>a</sup>	Nitroprusside, isosorbide dinitrate, nitroglycerin		
Phosphodiesterase E5 inhibitors	Sildenafil, vardenafil, tadalafil		
Vasodilators			
Alpha-1 adrenergic antagonists <sup>a</sup>	Alfuzosin, doxazosin, prazosin, terazosin, tamsulosin (used primarily for benign prostatic hyperplasia		
Dihydropyridine calcium channel blockers	Amlodipine, nifedipine, nicardipine		
Other direct vasodilators	Hydralazine, minoxidil		
Negative inotropic/chronotropic agent.	S		
Beta-adrenergic blockers	Propranolol, metoprolol, atenolol, bisoprolol, nebivolol (also vasodilator), carvedilol (also alpha-1 antagonist), labetalol (also alpha-1 antagonist)		
Non-dihydropyridine calcium channel blockers	Verapamil, diltiazem		
Central sympatholytic agents			
Centrally acting alpha-2 agonists	Clonidine		
False neurotransmitters	Alpha-methyldopa		
Renin–angiotensin system (RAS) antag	gonists		
Angiotensin converting enzyme (ACE) inhibitors	Captopril, enalapril, perindopril,		
Angiotensin receptor type II blockers (ARB)	Losartan, telmisartan, candesartan		





### Grazie per l'attenzione

Martina Rafanelli, MD, PhD

Syncope Unit, SOD di Geriatria e UTIG, Università degli Studi di Firenze, Azienda Ospedaliero-Universitaria Careggi, Firenze



